SCYX Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2023-05-01 | 2022 | Scott Sukenick General Counsel | 395,283 | 0 | 223,850 | 103,700 | 43,071 | 976,807 |
| 2023-05-01 | 2022 | Marco Taglietti, M.D. Former President and Chief Executive Officer | 598,637 | 0 | 479,600 | 186,000 | 645,555 | 2,608,785 |
| 2023-05-01 | 2021 | Marco Taglietti, M.D. Former President and Chief Executive Officer | 569,545 | 0 | 0 | 287,000 | 49,373 | 1,714,217 |
| 2023-05-01 | 2022 | Christine Coyne Former Chief Commercial Officer | 369,726 | 0 | 237,600 | 83,000 | 247,903 | 1,164,197 |
| 2023-05-01 | 2021 | Christine Coyne Former Chief Commercial Officer | 254,509 | 0 | 97,500 | 135,000 | 25,073 | 1,033,194 |
| 2023-05-01 | 2022 | David Angulo, M.D. President and Chief Executive Officer | 482,326 | 0 | 281,050 | 125,700 | 23,662 | 1,168,835 |
| 2023-05-01 | 2021 | David Angulo, M.D. President and Chief Executive Officer | 461,228 | 0 | 0 | 179,900 | 37,292 | 987,475 |
| 2022-05-12 | 2021 | Marco Taglietti, M.D. President and Chief Executive Officer | 569,545 | 0 | 0 | 287,000 | 49,373 | 1,714,217 |
| 2022-05-12 | 2020 | Marco Taglietti, M.D. President and Chief Executive Officer | 552,970 | 0 | 0 | 386,000 | 52,300 | 1,449,548 |
| 2022-05-12 | 2021 | Christine Coyne Chief Commercial Officer | 254,509 | 0 | 97,500 | 135,000 | 25,073 | 1,033,194 |
| 2022-05-12 | 2021 | David Angulo, M.D. Chief Medical Officer | 461,228 | 0 | 0 | 179,900 | 37,292 | 987,475 |
| 2022-05-12 | 2020 | David Angulo, M.D. Chief Medical Officer | 447,301 | 0 | 0 | 227,500 | 34,862 | 938,803 |
| 2021-04-26 | 2019 | David Angulo, M.D. Chief Medical Officer | 436,967 | 0 | 207,000 | 201,990 | 37,169 | 1,011,106 |
| 2021-04-26 | 2020 | David Angulo, M.D. Chief Medical Officer | 447,301 | 0 | 0 | 227,500 | 34,862 | 938,803 |
| 2021-04-26 | 2019 | Eric Francois Chief Financial Officer | 380,733 | 0 | 172,500 | 176,000 | 48,174 | 884,057 |
| 2021-04-26 | 2020 | Eric Francois Chief Financial Officer | 391,343 | 0 | 0 | 198,200 | 44,707 | 825,198 |
| 2021-04-26 | 2019 | Marco Taglietti, M.D. President and Chief Executive Officer | 542,500 | 0 | 0 | 344,720 | 50,125 | 1,534,585 |
| 2021-04-26 | 2020 | Marco Taglietti, M.D. President and Chief Executive Officer | 552,970 | 0 | 0 | 386,000 | 52,300 | 1,449,548 |
| 2020-05-29 | 2018 | Marco Taglietti, M.D. President and Chief Executive Officer | 526,666 | 0 | 0 | 219,000 | 44,779 | 1,114,895 |
| 2020-05-29 | 2019 | Marco Taglietti, M.D. President and Chief Executive Officer | 542,500 | 0 | 0 | 344,720 | 50,125 | 1,534,585 |
| 2020-05-29 | 2018 | Eric Francois Chief Financial Officer | 369,583 | 0 | 0 | 125,000 | 40,338 | 664,701 |
| 2020-05-29 | 2019 | David Angulo, M.D. Chief Medical Officer | 436,967 | 0 | 207,000 | 201,990 | 37,169 | 1,011,106 |
| 2020-05-29 | 2018 | David Angulo, M.D. Chief Medical Officer | 424,216 | 0 | 0 | 150,000 | 21,355 | 768,611 |
| 2020-05-29 | 2019 | Eric Francois Chief Financial Officer | 380,733 | 0 | 172,500 | 176,000 | 48,174 | 884,057 |
| 2019-05-07 | 2017 | David Angulo, M.D. Chief Medical Officer | 411,783 | 124,200 | 0 | 0 | 18,077 | 767,546 |
| 2019-05-07 | 2018 | David Angulo, M.D. Chief Medical Officer | 424,216 | 150,000 | 0 | 0 | 21,355 | 768,611 |
| 2019-05-07 | 2017 | Eric Francois Chief Financial Officer | 358,750 | 97,400 | 0 | 0 | 37,017 | 645,657 |
| 2019-05-07 | 2018 | Eric Francois Chief Financial Officer | 369,583 | 125,000 | 0 | 0 | 40,338 | 664,701 |
| 2019-05-07 | 2018 | Marco Taglietti, M.D. President and Chief Executive Officer | 526,666 | 219,000 | 0 | 0 | 44,779 | 1,114,895 |
| 2019-05-07 | 2017 | Marco Taglietti, M.D. President and Chief Executive Officer | 507,400 | 140,300 | 0 | 0 | 23,984 | 1,220,648 |
| 2018-04-30 | 2017 | David Angulo, M.D. Chief Medical Officer | 411,783 | 124,200 | 0 | 0 | 18,077 | 767,546 |
| 2018-04-30 | 2016 | Eric Francois Chief Financial Officer | 350,000 | 113,000 | 0 | 0 | 35,954 | 548,743 |
| 2018-04-30 | 2017 | Eric Francois Chief Financial Officer | 358,750 | 97,400 | 0 | 0 | 37,017 | 645,657 |
| 2018-04-30 | 2016 | Marco Taglietti, M.D. President and Chief Executive Officer | 490,800 | 210,100 | 0 | 0 | 18,742 | 1,180,284 |
| 2018-04-30 | 2017 | Marco Taglietti, M.D. President and Chief Executive Officer | 507,400 | 140,300 | 0 | 0 | 23,984 | 1,220,648 |
| 2018-04-30 | 2016 | David Angulo, M.D. Chief Medical Officer | 398,775 | 136,600 | 0 | 0 | 95,959 | 805,596 |
| 2017-04-26 | 2016 | Eric Francois Chief Financial Officer | 350,000 | 113,000 | 0 | 0 | 35,954 | 548,743 |
| 2017-04-26 | 2016 | Marco Taglietti, M.D. President and Chief Executive Officer | 490,800 | 210,100 | 0 | 0 | 18,742 | 1,180,284 |
| 2017-04-26 | 2015 | Marco Taglietti, M.D. President and Chief Executive Officer | 360,000 | 264,000 | 0 | 0 | 3,743 | 2,317,805 |
| 2017-04-26 | 2015 | Eric Francois Chief Financial Officer | 58,333 | 20,300 | 0 | 0 | 3,453 | 487,678 |
| 2017-04-26 | 2016 | David Angulo, M.D. Chief Medical Officer | 398,775 | 136,600 | 0 | 0 | 95,959 | 805,596 |
| 2017-04-26 | 2015 | David Angulo, M.D. Chief Medical Officer | 227,500 | 117,000 | 0 | 0 | 67,873 | 1,050,607 |
| 2016-04-21 | 2015 | Marco Taglietti, M.D. | 360,000 | 264,000 | 0 | 0 | 3,743 | 2,317,805 |
| 2016-04-21 | 2014 | Yves J. Ribeill, Ph.D. Director, Former CEO | 337,556 | 195,600 | 0 | 0 | 9,654 | 1,341,242 |
| 2016-04-21 | 2015 | Eric Francois | 58,333 | 20,300 | 0 | 0 | 3,453 | 487,678 |
| 2016-04-21 | 2015 | David Angulo, M.D. | 227,500 | 117,000 | 0 | 0 | 67,873 | 1,050,607 |
| 2016-04-21 | 2015 | Charles F. Osborne, Jr. Former Chief Financial Officer | 148,818 | 55,000 | 0 | 0 | 360,675 | 851,407 |
| 2016-04-21 | 2014 | Charles F. Osborne, Jr. Former Chief Financial Officer | 272,127 | 59,999 | 0 | 0 | 9,172 | 579,069 |
| 2016-04-21 | 2015 | Yves J. Ribeill, Ph.D. Director, Former CEO | 222,821 | 100,000 | 0 | 0 | 982,540 | 2,613,348 |
| 2015-04-22 | 2014 | Yves J. Ribeill, Ph.D. President and Chief Executive Officer | 337,556 | 195,600 | 0 | 0 | 9,654 | 1,341,242 |
| 2015-04-22 | 2013 | Carole Sable Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2015-04-22 | 2014 | Carole Sable Chief Medical Officer | 336,762 | 86,520 | 0 | 0 | 4,483 | 2,007,422 |
| 2015-04-22 | 2013 | Charles F. Osborne, Jr. Chief Financial Officer | 250,205 | 0 | 0 | 0 | 8,955 | 259,160 |
| 2015-04-22 | 2014 | Charles F. Osborne, Jr. Chief Financial Officer | 272,127 | 59,999 | 0 | 0 | 9,172 | 579,069 |
| 2015-04-22 | 2013 | Yves J. Ribeill, Ph.D. President and Chief Executive Officer | 250,146 | 0 | 0 | 0 | 11,904 | 262,050 |
| 2014-08-01 | 2013 | Yves J. Ribeill, Ph.D. President and Chief Executive Officer | 250,146 | 0 | 0 | 0 | 11,904 | 262,050 |
| 2014-08-01 | 2013 | Charles F. Osborne, Jr. Chief Financial Officer | 250,205 | 0 | 0 | 0 | 8,955 | 259,160 |
| 2014-08-01 | 2012 | Charles F. Osborne, Jr. Chief Financial Officer | 250,213 | 0 | 0 | 0 | 8,779 | 258,992 |
| 2014-08-01 | 2013 | Eileen C. Pruette General Counsel | 235,062 | 0 | 0 | 0 | 8,477 | 243,539 |
| 2014-08-01 | 2012 | Eileen C. Pruette General Counsel | 87,372 | 0 | 0 | 0 | 2,687 | 232,059 |
| 2014-08-01 | 2012 | Yves J. Ribeill, Ph.D. President and Chief Executive Officer | 250,203 | 0 | 0 | 0 | 10,080 | 260,283 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
